HBI 2376
Alternative Names: GH-21; HBI-2376Latest Information Update: 16 Sep 2025
At a glance
- Originator Suzhou Genhouse Bio
- Developer HUYA Bioscience International; Suzhou Genhouse Bio
- Class Antineoplastics; Small molecules
- Mechanism of Action Protein tyrosine phosphatase non-receptor type 11 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Solid tumours
- Phase I/II Non-small cell lung cancer
Most Recent Events
- 16 Sep 2025 Drug is still in phase-I development in Solid-tumours (Late-stage disease, Metastatic disease) in China (PO, Capsule) (NCT05183243)
- 16 Sep 2025 HBI 2376 is still in phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)
- 13 Aug 2025 Chia Tai Tianqing Pharmaceutical Group enters into clinical collaboration with Genhouse Bio, before August 2025 (Suzhou GenHouse Bio pipeline, August 2025)